An interventional study of transcranial Direct Current Stimulation (tDCS) and Transcranial Ultrasound (TUS) in Chronic Pain and Carpal Tunnel Syndrome, sponsored by Spaulding Rehabilitation Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Spaulding Rehabilitation Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital — 3 open to participants now, 5 under way, none of them phase 3. Chronic Pain · Spaulding Rehabilitation Hospital.
Among the 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital, this one is the 2nd largest by planned enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2021, is one of 15 with no phase, and was the 13th registered.
3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →3 of the 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital are open now, in 1 country. Recruiting first, the newest first:
Spaulding Rehabilitation Hospital · Sites in United States
Ages 18–65
Spaulding Rehabilitation Hospital
Ages 18–65
By country, each count listing its studies:
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2021.
This study's planned enrollment of 95 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 38 across the 15 interventional studies, 20 across the 1 observational. Of the 11 that completed or were terminated, 1 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
Spaulding Rehabilitation Hospital is the lead sponsor of 118 studies on the registry; 27 are open to participants now.
Of its 20 completed or terminated interventional studies of FDA-regulated products, 17 (85%) have results posted.
2 of the studies in Chronic Pain by Spaulding Rehabilitation Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06157866Spaulding Rehabilitation HospitalCognitive Training to Enhance Brain Concordance During Acupuncture | 2027-06-30 |
| NCT04206215Spaulding Rehabilitation HospitalNoninvasive Brain Stimulation for Treating Carpal Tunnel Syndrome | 2027-07-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Chronic Pain by Spaulding Rehabilitation Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the effects of tDCS in combination with TUS for the treatment of pain in subjects with Carpal Tunnel Syndrome. The investigators hypothesize that there will be a decrease in pain levels with active stimulation, when compared to sham stimulation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
to tDCS+TUS:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS).
Device: transcranial Direct Current Stimulation (tDCS) · Device: Transcranial Ultrasound (TUS)
Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
Device: transcranial Direct Current Stimulation (tDCS) · Device: Transcranial Ultrasound (TUS)
Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. In the sham group, the tDCS device will not be active for the full 20 minutes.
Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
Visual Analogue Score (VAS)
Changes in the Visual Analogue Scale (VAS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in reducing pain in subjects with Carpal Tunnel Syndrome. The VAS scale goes from 0 up to 10, where 0 means no pain at all and 10 means the worst imaginable pain.
Time frame: 9 weeks
Verbal Rating Scale (VRS)
Changes in the Verbal Rating Scale (VRS) for pain will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in reducing pain in subjects with Carpal Tunnel Syndrome. The VRS minimum value is no pain and the maximum value is severe pain. Being severe pain the worst outcome.
Time frame: Measured for approximately for a total 9 weeks
Visual Analog Mood Scale (VAMS)
The investigators will measure safety of tDCS and TUS by measuring changes in the Visual Analog Mood Scale. This scale will range from zero (low or worst mood) to 10 on anxiety, depression, sleepiness and stress.
Time frame: Measured for approximately for a total 9 weeks
Montreal Cognitive Assessment (MOCA)
The investigators will monitor the safety of tDCS and TUS in subjects by measuring any changes in cognition, attention, and focus with the MOCA. MOCA scores range between 0 and 30, a score of 26 and higher generally considered normal.
Time frame: Measured for approximately for a total 9 weeks
tDCS Side Effects Questionnaire
At each session, subjects will complete a questionnaire to evaluate potential adverse effects of stimulation (headache, neck pain, mood alterations, and seizures) on a 4-point scale, where 1 is absent and 4 is severe. The scale will also be administered at the follow-ups.
Time frame: Measured for approximately for a total 9 weeks
Patient Health Questionnaire (PHQ-9)
The investigators will measure safety of tDCS and TUS by measuring changes of mood through the PHQ-9. The scoring goes from 0 to 27, where 0 is no depression and 27 is severe depression.
Time frame: Measured for approximately for a total 9 weeks
Multidimensional Pain Inventory (MPI)
The investigators will monitor the impact of pain with the MPI of tDCS and TUS. It consist in 3 sections (Pain Impact , responses by significant others, activities and each item is rated on a 7-point scale (0-6), where higher scores represent severe symptoms .
Time frame: Measured for approximately for a total 9 weeks
Neuropathic Pain Symptom Inventory (NPSI)
The investigators will monitor the changes of neuropathic pain in subjects going through the study before and after tDCS and TUS. It include 12 items in total, this tool evaluates mean pain intensity in the last 24 hours in a numeric scale from zero (no pain) to 10 (worst imaginable pain). Total pain intensity score may be calculated by the sum of 10 descriptors
Time frame: Measured for approximately for a total 9 weeks
Temporal Summation (TS)
The investigators will monitor the changes of temporal summation in the study before and after tDCS and TUS. This will be assessed by Von Frey filaments. This is assessed by having the participant rate their pain after a single stimulus (6.65, 300 g) applied for 0.5 s and then again after a series of 10 (6.65, 300 g) stimuli are applied at 1-s intervals.
Time frame: Measured for approximately for a total 9 weeks
Conditioned pain modulation (CPM)
Changes in the conditioned pain modulation will be measured in order to determine whether anodal transcranial direct current stimulation in conjunction with transcranial ultrasound is effective in changing the conditioned pain modulation system in subjects with Carpal Tunnel Syndrome. This will be assessed by applying pressure with an algometer.
Time frame: Measured for approximately for a total 9 weeks
Vibration Detection Threshold (VDT)
Changes in the vibration detection threshold will be measured , this is performed with a Rydel-Seiffer tuning fork (64 Hz, 8/8 scale) placed on the skin surface and is determined by asking the participant to tell the examiner when the vibration is no longer felt.
Time frame: Measured for approximately for a total 9 weeks
Michigan Hand Outcomes Questionnaire (MHQ)
This a hand-specific outcomes instrument that measures outcomes of patients with conditions of, or injury to, the hand or wrist. The MHQ contains six distinct scales: overall hand function, activities of daily living , pain, work performance, aesthetics, and patient satisfaction with hand function. They are scored from 0 - 100 in which 100 is the best possible ability
Time frame: Measured for approximately for a total 9 weeks
Boston Carpal Tunnel Questionnaire
This is an instrument specifically designed for Carpal Tunnel Syndrome (CTS) and validated for CTS therapy assessments (consisting of the Functional Status Scale and Symptom Severity Scale scores. The symptom severity scale has 11 questions scored from 1 point (mildest) to 5 points (most severe).
Time frame: Measured for approximately for a total 9 weeks
The Medical Outcomes Study 36-Item Short Form (SF-36)
This a generic health status instrument that measures 8-health related concepts using 36 questions and provides a profile of functional health and well-being scores. It also provides a psychometrical index of physical and mental health. Each scale is transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability
Time frame: Measured for approximately for a total 9 weeks
Electroencephalography (EEG)
Investigators will measure electroencephalogram activity to monitor safety. Baseline recordings will be reviewed to ensure that there are no potential electroencephalographic safety criteria prior to stimulation. This qualitative analysis will focus on pathological EEG activity such as epileptiform discharges or persistent focal slowing.
Time frame: Measured for approximately for a total 3 weeks
Strength (grip and pinch)
Strength will be assessed using a grip dynamometer and a pinch dynamometer
Time frame: Measured for approximately for a total 9 weeks
Range of Motion (ROM)
The investigators will assess active and passive ROM in the elbow, forearm, wrist, thumb, digits
Time frame: Measured for approximately for a total 9 weeks
Thumb Reaching Test
Subject will be asked to reach the base of the little finger with their thumb. The task will be repeated up to 10 times. Primary data will be taken from inertial sensors placed on the thumb and little finger.
Time frame: Measured for approximately for a total 9 weeks
Reach to Pinch
Subject will be asked to perform a reach to pinch task . The task will be repeated up to 10 times. Primary data will be taken from camera and accelerometers/gyroscopes placed on the thumb and index finger.
Time frame: Measured for approximately for a total 9 weeks
Wrist Flexion-Extension:
Subject will be asked to flex-extend their wrist up to 10 times. Primary data will be taken from an accelerometer/gyroscope placed on the wrist and the camera.
Time frame: Measured for approximately for a total 9 weeks
Started Apr 2021 (actual). Primary completion is estimated for Jul 2027, 74 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 74 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spaulding Rehabilitation Hospital →